Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study-Reference-Cited by-同舟云学术

Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study

Published:2013-11-20 Issue:3 Volume:20 Page:362-368
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Windyga J.¹,Lin V. W.²,Epstein J. D.²,Ito D.²,Xiong Y.²,Abbuehl B. E.³,Ramirez J. H.⁴

Affiliation:

1. Institute of Hematology and Transfusion Medicine; Warsaw Poland

2. Baxter BioScience; Westlake Village CA USA

3. Baxter Innovations GmbH; Vienna Austria

4. Centro Medico Imbanaco; Cali Colombia

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12315/fullpdf

Reference20 articles.

1. Haemophilias A and B;Bolton-Maggs;Lancet,2003

2. Haemophilia B: impact on patients and economic burden of disease;Gater;Thromb Haemost,2011

3. Haemophilia B: current pharmacotherapy and future directions;Franchini;Expert Opin Pharmacother,2012

4. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries;Noone;Haemophilia,2013

5. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia;Uijl;Haemophilia,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe;Orphanet Journal of Rare Diseases;2021-12

3. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B;Cochrane Database of Systematic Reviews;2021-08-18

4. Association between reported medication adherence and health-related quality of life in adult patients with haemophilia;International Journal of Clinical Pharmacy;2021-04-29

5. Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry;Iraqi Journal of Hematology;2021